Select Language
COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
Market Overview:
The global hepatitis diagnostic tests market reached a value of US$ 5.3 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7.24 Billion by 2027, exhibiting at a CAGR of 5.25% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Hepatitis represents a major global health threat that requires an urgent response. According to estimates, hepatitis causes 1.3 Million-1.5 Million deaths each year, a figure that is comparable to the deaths caused by tuberculosis and even higher than those caused by HIV. Moreover, while mortality from diseases such as HIV, tuberculosis, and malaria are now declining, mortality from hepatitis has been rising. According to estimates around 325-350 Million people across the globe are carriers of hepatitis B or C virus infections, which may remain asymptomatic for decades. Moreover, every year, around 1.75 Million people get infected by the hepatitis C virus infection. Unless these people receive timely testing and treatment, they are at risk of severe liver disease and even death. Diagnostic tests help in the early detection of hepatitis infections and increase the chances of survival of the patient by correct medication and treatment.
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
The global demand of hepatitis diagnostic tests is currently exhibiting strong growth. This market is currently being catalyzed by a number of factors such as the increasing burden of hepatitis across the globe, rising number of blood transfusions and donations, technological advancements and the advantages offered by PoC (Point of Care) test, and rising awareness levels. A major trend being witnessed in this market has been a shift from conventional testing methods to molecular diagnostics. This has resulted in an increased accuracy and reduced the total time required to get the results.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hepatitis diagnostic tests market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on test type.
Breakup by Test Type:
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
Based on the test type, the market has been segmented into blood tests, imaging test and liver biopsy. Blood tests currently represent the biggest application. Blood tests are further segmented into liver function test, immunoassays, and nucleic acid tests. Liver function tests currently represent the biggest segment.
Breakup by Region:
www.imarcgroup.com
To get more information on the regional analysis of this market, Request Sample
Region-wise, the market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa and Latin America. Amongst these, North America is the biggest market, accounting for the majority of the global market.
Competitive Landscape:
The competitive landscape of the market has also been examined with some of the key players being Siemens AG, Abbott Laboratories, MedMira Inc, Qaigen Inc, Beckman Coulter Inc (Danaher Corporation), F. Hoffmann Roche, Diasorin S.p.A, bioMeriuex, Hologic Inc and Bio-Rad Laboratories Inc.
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2021 |
| Historical Period | 2016-2021 |
| Forecast Period | 2022-2027 |
| Units | US$ Billion |
| Segment Coverage | Test Type, Region |
| Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Companies Covered | Siemens AG, Abbott Laboratories, MedMira Inc, Qaigen Inc, Beckman Coulter Inc (Danaher Corporation), F. Hoffmann Roche, Diasorin S.p.A, bioMeriuex, Hologic Inc and Bio-Rad Laboratories Inc. |
| Customization Scope | 10% Free Customization |
| Report Price and Purchase Option | Single User License: US$ 2499 Five User License: US$ 3499 Corporate License: US$ 4499 |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
10% Free customization
Purchase Options
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at
sales@imarcgroup.com